Clinical

Moreau de Tours on dawamesc, self-experiment, and experimental psychiatry

Selected passages from Moreau de Tours's 1845 psychiatric treatise on hashish, including his insistence on personal experience, description of dawamesc preparation and dosing, and claim that hashish offered a unique experimental route into the psychology of madness.

Side Effects and Complications

Sidney Cohen surveyed researchers at the VA Neuropsychiatric Hospital who had administered LSD or mescaline to nearly 5,000 subjects across more than 25,000 doses. He found no cases of serious prolonged physical harm and quantified low rates of suicide attempts, psychotic breaks over 48 hours, and other adverse effects.

A Chilean psychiatrist's report on harmala alkaloids, ayahuasca-related beta-carbolines, and comparative human experiments with harmaline and mescaline at the University of Chile.

Rockefeller Commission findings on CIA drug testing and domestic activities

The Rockefeller Commission's 1975 report was the first major presidential inquiry to put CIA drug experiments, including LSD-related episodes and the death of Frank Olson, into an official public account. It became a bridge between the commission investigation, the Church Committee, and the later Senate MKULTRA hearing.

Full Senate report including the chapter on chemical and biological agents

Book I of the Church Committee final report, Foreign and Military Intelligence, includes the committee's findings on CIA testing and use of chemical and biological agents. The full volume places MKULTRA and LSD-related experimentation within broader findings on covert action, intelligence oversight, and congressional accountability.

1977 Senate joint hearing on LSD, behavioral research, and CIA records

A joint Senate hearing on Project MKULTRA after CIA director Stansfield Turner informed Congress that financial records had surfaced for previously destroyed behavioral-research files. The hearing and appendices document LSD-related projects, agency recordkeeping, and congressional oversight of CIA human-subjects research.

An Update (NIDA Research Monograph 146)

Proceedings of a 1992 NIDA technical review on hallucinogen research, prompted by rising LSD use among teenagers. Includes Rick Strassman's account of the regulatory process (IRB, DEA, FDA) for his DMT study, the first human hallucinogen study approved since the early 1970s.